Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Nurix promotes O’Connor to CMO, Phiasivongsa to CTO

Plus: NodThera names Daniel Swisher CEO, and updates from Cogent, Sapreme and Biocom

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
May 29, 2024 12:38 AM UTC

Protein modulation therapies company Nurix Therapeutics Inc. (NASDAQ:NRIX) promoted Paula O’Connor to CMO from EVP and head of clinical development, and Pasit Phiasivongsa to CTO from EVP of technical operations.

NodThera Ltd. named Daniel Swisher CEO, succeeding interim CEO Alan Watt, who will become president and CSO. Swisher was president and COO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Biocom

Cogent Biosciences Inc.

Nodthera Ltd.

Nurix Therapeutics Inc.

Sapreme Technologies B.V.